Funding for this research was provided by:
National Institute of Child Health and Human Development (HD062844)
Received: 18 July 2018
Accepted: 4 January 2019
First Online: 14 January 2019
Ethics approval and consent to participate
: Each study participant gave written informed consent under protocol NA_00083620, approved by the Johns Hopkins Medicine Institutional Review Board on Human Subject Research.
: Not applicable.
: DOH, RAC, and TRM have applied for the following patents: Compositions and Methods for Inactivation of Pathogens at Genital Tract Surfaces (U.S. Patent Application number 20120070476), and Reusable Intravaginal Delivery Device, System, and Method (U.S. Patent Application number 20120296315), with patent assignment to ReProtect Inc., Baltimore MD., and Johns Hopkins University, Baltimore MD. RAC and TRM are employed by ReProtect Inc. (Chair of Board, and President/Chief Operating Officer respectively) and hold equity in the company. This does not alter our adherence to BMC Microbiology policies on sharing data and materials.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.